MAPT RNA interference agents

MAPT RNAi agents are developed to specifically target and reduce MAPT gene expression, addressing the lack of effective treatments for tauopathies by utilizing RNA interference mechanisms.

JP2024545202AActive Publication Date: 2024-12-05ELI LILLY & CO
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024535204
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-13
Filing Date
2022-12-12
Publication Date
2024-12-05
Estimated Expiration
2042-12-12

AI Technical Summary

Technical Problem

There are no FDA-approved disease-modifying therapeutics specifically targeting the MAPT gene for treating tauopathies, and existing treatments like aducanumab focus on amyloid beta protein rather than addressing the underlying tau pathology.

Method used

Development of MAPT RNAi agents comprising specific nucleic acid sequences with high sequence identity to target MAPT gene expression, utilizing sense and antisense strands to form a duplex and potentially reduce MAPT expression through RNA interference.

Benefits of technology

The MAPT RNAi agents effectively target and reduce MAPT expression, providing a therapeutic approach to treat tauopathies by modulating MAPT gene activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545202000001
    Figure 2024545202000001
  • Figure 2024545202000002
    Figure 2024545202000002
  • Figure 2024545202000003
    Figure 2024545202000003
Patent Text Reader

Abstract

Provided herein are MAPT RNAi agents and compositions comprising MAPT RNAi agents. Also provided herein are methods of using MAPT RNAi agents or compositions comprising MAPT RNAi agents to reduce MAPT expression in a subject and / or to treat tauopathy.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Sequence Listing This application has been submitted with a Sequence Listing in ST.26XML format. The Sequence Listing is provided in file entitled "30170", created on November 2, 2022, and is 835 kilobytes in size. The Sequence Listing information in ST.26XML format is incorporated herein by reference in its entirety. [Background technology]

[0002] The microtubule-associated protein tau is encoded by the MAPT gene located on chromosome 17. Tau protein interacts with tubulin to stabilize microtubules and promotes tubulin assembly into microtubules. MAPT transcripts are differentially expressed throughout the body, primarily in the central and peripheral nervous systems.

[0003] The MAPT gene consists of 16 exons. Alternative mRNA splicing gives rise to multiple MAPT isoforms. At least six tau isoforms exist in the human brain, ranging from 352 to 441 amino acids in length. Alternative splicing of exon 2 and / or exon 3 results in the inclusion of 0, 1, or 2 copies of the N-terminal acidic domain, which are referred to as 0N, 1N, or 2N tau, respectively. Tau isoforms that contain exon 10, which encodes an additional microtubule-binding domain, are referred to as "4R tau (4RTau)" since they have four microtubule-binding domains. Tau isoforms that do not contain exon 10 are referred to as "3R tau (3R Tau)" since they have three microtubule-binding domains.

[0004] Mutations in MAPT and hyperphosphorylation of tau protein lead to the aggregation and deposition of tau in pathogenic neurofibrillary tangles, which can lead to progressive neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia (FTD), Progressive Supranuclear Palsy (PSP), and other tauopathies.

[0005] RNA interference (RNAi) is a highly conserved regulatory mechanism in which RNA molecules are involved in sequence-specific gene suppression of gene expression by double-stranded RNA molecules (dsRNA) (Fire et al., Nature 391:806-811, 1998).

[0006] Currently, there is no FDA (Food and Drug Administration) approved disease-modifying therapeutic agent for specifically reducing MAPT and treating tauopathy. Aducanumab, which targets amyloid beta protein (Aβ), is the only disease-modifying drug currently approved for treating Alzheimer's disease. Therefore, there is still a need for therapeutic agents that can inhibit or regulate the expression of MAPT gene to treat tauopathy, for example, by utilizing RNAi. Summary of the Invention

[0007] Provided herein are MAPT RNAi agents and compositions comprising MAPT RNAi agents. Also provided herein are methods of using MAPT RNAi agents or compositions comprising MAPT RNAi agents to reduce MAPT expression in a subject and / or to treat tauopathy.

[0008] In one aspect, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:1, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:2; (b) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:3, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:4; (c) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:5, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:6; (d) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:7, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:8; (e) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:9, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:10; (f) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:11, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:12; (g) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 13, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 14; (h) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 15, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 16; (i) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 17, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 18; (j) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 19, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 20; (k) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:21, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:22; (l) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 23, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 24; (m) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:55, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:16; (n) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:56, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:16; (o) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:57, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:58; (p) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:59, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:58; (q) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 60, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 61; (r) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 62, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 61; (s) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 117, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 118, and (t) a sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 119, and an antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 16. A MAPT RNAi agent comprising a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0009] In some embodiments, the sense and antisense strands of the MAPT RNAi agents described herein are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 59, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (q) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16. The nucleic acid sequence comprises a pair of nucleic acid sequences selected from the group consisting of:

[0010] In some embodiments, the sense and antisense strands of the MAPT RNAi agents described herein are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand having a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand having a first nucleic acid sequence of SEQ ID NO:59, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:58; (q) a sense strand having a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand having a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand having a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16. The nucleic acid sequence of the present invention is selected from the group consisting of:

[0011] The MAPT RNAi agents described herein may include a modifying agent. The modification may be made to one or more nucleotides of the sense strand and / or the antisense strand, or to the internucleotide linkage. In some embodiments, one or more nucleotides of the sense strand are modified nucleotides. In some embodiments, each nucleotide of the sense strand is a modified nucleotide. In some embodiments, one or more nucleotides of the antisense strand are modified nucleotides. In some embodiments, each nucleotide of the antisense strand is a modified nucleotide. In some embodiments, the modified nucleotide is a 2'-fluoro modified nucleotide, a 2'-Om-methyl modified nucleotide, or a 2'-O-alkyl modified nucleotide, such as a 2'-O-C16 alkyl modified nucleotide. In some embodiments, the sense strand has four 2'-fluoro modified nucleotides at positions 7, 9, 10, and 11 from the 5' end of the sense strand. In some embodiments, the nucleotides at positions other than 7, 9, 10, and 11 of the sense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides. In some embodiments, the antisense strand has four 2'-fluoro modified nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the nucleotides at positions other than positions 2, 6, 14, and 16 of the antisense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides. In some embodiments, the sense strand has three 2'-fluoro modified nucleotides, for example, at positions 9, 10, and 11 from the 5' end of the sense strand. In some embodiments, the other nucleotides of the sense strand are 2'-O-methyl modified nucleotides. In some embodiments, the antisense strand has five 2'-fluoro modified nucleotides, for example, at positions 2, 5, 7, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the antisense strand has five 2'-fluoro modified nucleotides, for example, at positions 2, 5, 8, 14, and 16 from the 5' end of the antisense strand.In some embodiments, the antisense strand has five 2'-fluoro modified nucleotides, e.g., at positions 2, 3, 7, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the remaining nucleotides in the antisense strand are 2'-O-methyl modified nucleotides. In some embodiments, the sense strand comprises an abasic moiety or an inverted abasic moiety.

[0012] In some embodiments, the first nucleotide from the 5' end of the antisense strand is a modified nucleotide having a phosphate analog, e.g., 5'-vinyl phosphonate. In some embodiments, the sense strand comprises an abasic portion or an inverted abasic portion. In some embodiments, the sense strand and the antisense strand have one or more modified internucleotide linkages, e.g., phosphorothioate linkages. In some embodiments, the sense strand has four or five phosphorothioate linkages. In some embodiments, the antisense strand has four or five phosphorothioate linkages. In some embodiments, the sense strand has four phosphorothioate linkages and the antisense strand has four phosphorothioate linkages.

[0013] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 63, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (n) a sense strand comprising a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NOs: 66 to 69, SEQ ID NO: 71, SEQ ID NOs: 75 to 86, and SEQ ID NOs: 93 to 100, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 64, and an antisense strand comprising a second nucleic acid sequence selected from any one of SEQ ID NO: 70 and SEQ ID NOs: 72 to 74; (p) a sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 88; (q) a sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 91; (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 101, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 102; (s) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 103, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 104; (t) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand comprising a second nucleic acid sequence selected from SEQ ID NO: 65, and any one of SEQ ID NOs: 106 to 108; (u) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (v) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (w) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:111, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:112; (x) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 114, and (y) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 116. The MAPT RNAi agent comprises a pair of nucleic acid sequences selected from the group consisting of:

[0014] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO: 63, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (n) a sense strand having a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NOs: 66 to 69, SEQ ID NO: 71, SEQ ID NOs: 75 to 86, and SEQ ID NOs: 93 to 100, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 64, and an antisense strand having a second nucleic acid sequence selected from any one of SEQ ID NO: 70 and SEQ ID NOs: 72 to 74; (p) a sense strand having a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 88; (q) a sense strand having a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 91; (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 101, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 102; (s) a sense strand having a first nucleic acid sequence of SEQ ID NO: 103, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 104; (t) a sense strand having a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand having a second nucleic acid sequence selected from SEQ ID NO: 65 and any one of SEQ ID NOs: 106 to 108; (u) a sense strand having a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (v) a sense strand having a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (w) a sense strand having a first nucleic acid sequence of SEQ ID NO:111, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:112; (x) a sense strand having a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 114, and (y) a sense strand having a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 116. The MAPT RNAi agent has a pair of nucleic acid sequences selected from the group consisting of:

[0015] In some embodiments, the sense strand of the MAPT RNAi agent has a delivery moiety. In some embodiments, the sense strand of the MAPT RNAi agent has a delivery moiety conjugated to the 5'-end or 3'-end of the sense strand. In some embodiments, the sense strand of the MAPT RNAi agent has a delivery moiety conjugated to a nucleotide of the sense strand. In some embodiments, the delivery moiety is α-tocopherol or palmitic acid. In some embodiments, the delivery moiety is conjugated to the 5'-end or 3'-end of the sense strand via a linker, e.g., a linker in Table 5.

[0016] In a further aspect, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a double stranded RNA (dsRNA) having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, and wherein the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 59, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (q) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16. comprising a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0017] In some embodiments, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a dsRNA having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, wherein the sense strand and the antisense strand are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand having a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand having a first nucleic acid sequence of SEQ ID NO:59, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:58; (q) a sense strand having a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand having a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand having a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16. having a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0018] In some embodiments, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a dsRNA having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, wherein the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand comprising a second nucleic acid sequence selected from SEQ ID NO: 65 and SEQ ID NOs: 106 to 108; (n) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (p) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 111, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 112; (q) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 114, and (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 116. The nucleic acid sequence comprises a pair of nucleic acid sequences selected from the group consisting of:

[0019] In some embodiments, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a dsRNA having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, wherein the sense strand and the antisense strand are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand having a second nucleic acid sequence selected from SEQ ID NO: 65 and SEQ ID NOs: 106 to 108; (n) a sense strand having a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (p) a sense strand having a first nucleic acid sequence of SEQ ID NO: 111, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 112; (q) a sense strand having a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 114, and (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 116. The nucleic acid sequence of the present invention is selected from the group consisting of:

[0020] In another aspect, provided herein is a pharmaceutical composition comprising the MAPT RNAi agent described herein and a pharmaceutically acceptable carrier.Also provided herein is a pharmaceutical composition comprising a means for reducing MAPT expression in cells and a pharmaceutically acceptable carrier.

[0021] In another aspect, provided herein is a method for reducing MAPT expression in a patient in need thereof, comprising administering to the patient an effective amount of a MAPT RNAi agent or pharmaceutical composition described herein.

[0022] In another aspect, provided herein is a method of treating a tauopathy in a patient in need thereof, comprising administering to the patient an effective amount of a MAPT RNAi agent or pharmaceutical composition described herein.

[0023] Also provided herein is a method of reducing MAPT expression in a cell (e.g., a neuron), which may include introducing a MAPT RNAi agent described herein into the cell and incubating the cell for a period of time sufficient to degrade MAPT mRNA, thereby reducing MAPT expression in the cell.

[0024] In another aspect, provided herein is a MAPT RNAi agent or a pharmaceutical composition comprising a MAPT RNAi agent for use in reducing MAPT expression.Also provided herein is a MAPT RNAi agent or a pharmaceutical composition comprising a MAPT RNAi agent for use in treatment.Also provided herein is a MAPT RNAi agent or a pharmaceutical composition comprising a MAPT RNAi agent for use in treating tauopathy.Also provided herein is the use of a MAPT RNAi agent in the manufacture of a medicament for treating tauopathy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Provided herein are MAPT RNAi agents and compositions comprising MAPT RNAi agents. Also provided herein are methods of using MAPT RNAi agents or compositions comprising MAPT RNAi agents to reduce MAPT expression in a subject and / or to treat tauopathy.

[0026] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex. The antisense strand is complementary to a region of MAPT mRNA. In further embodiments, the sense strand and the antisense strand are each 15-30 nucleotides in length, for example, 20-25 nucleotides in length. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand of 21 nucleotides and an antisense strand of 23 nucleotides. In some embodiments, the sense strand and the antisense strand of the MAPT RNAi agent may have an overhang (i.e., a 5' overhang or a 3' overhang) at either the 5' or 3' end. For example, the sense strand and the antisense strand may have a 5' or 3' overhang of 1-5 nucleotides or 1-3 nucleotides. In some embodiments, the antisense strand comprises a 3' overhang of 2 nucleotides. In some embodiments, the sense strand and the antisense strand sequences of the MAPT RNAi agent are provided in Table 1.

[0027] Provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:1, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:2; (b) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:3, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:4; (c) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:5, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:6; (d) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:7, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:8; (e) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:9, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:10; (f) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:11, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:12; (g) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:13, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:14; (h) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:15, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:16; (i) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:17, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:18; (j) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:19, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:20; (k) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:21, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:22; (l) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:23, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:24; (m) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:55, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:16; (n) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:56, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:16; (o) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:57, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:58; (p) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:59, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:58; (q) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 60, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 61; (r) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:62, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:61; (s) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:117, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:118; (t) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:119, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:16. A MAPT RNAi agent comprising a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0028] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:1, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:2, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:3, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:4, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:5, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:6, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:7, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:8, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 9, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 10, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 11, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 12, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 13, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 14, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 15, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 16, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 17, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 18, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 19, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 20, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:21, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:22, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:23, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:24, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:55, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:16, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 56, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:57, and the antisense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:58. about 97%, about 98%, about 99%, or about 100%) sequence identity to the first nucleic acid sequence, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:59, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:58, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 60, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 61, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 62, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 61, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 117, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 118, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 119, and the antisense strand comprises a second nucleic acid sequence having at least 95% (e.g., about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0029] [Table 1] In some embodiments, the sense and antisense strands of the MAPT RNAi agents described herein are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 59, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (q) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16. comprising a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0030] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 1, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 2, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 3, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 4, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 5, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 6, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 7, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 8, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 9, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 10, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 11, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 12, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 13, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 14, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 15, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 17, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 18, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 19, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 20, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 21, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 22, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 23, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 24, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 55, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 56, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 57, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 58, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 59, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 58, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 57, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 58, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 60, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 61, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 62, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 61, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 117, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 118, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 119, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 16, and wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0031] In some embodiments, the sense and antisense strands of the MAPT RNAi agents described herein are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand having a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand having a first nucleic acid sequence of SEQ ID NO:59, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:58; (q) a sense strand having a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand having a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand having a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16. having a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0032] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 1, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 2, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 3, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 4, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 5, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 6, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 7, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 8, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 9, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 10, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 11, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 12, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 13, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 14, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 15, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 16, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 17, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 18, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 19, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 20, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 21, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 22, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 23, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 24, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 55, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 56, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 16, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 57, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 58, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 59, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 58, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 60, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 61, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 62, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 61, and one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 117, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 118, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 119, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 16, wherein one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0033] In some embodiments, the MAPT RNAi agents described herein may comprise a sense strand that comprises a sequence that has one, two, or three differences from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:117, SEQ ID NO:119. In some embodiments, the MAPT RNAi agents described herein may comprise an antisense strand that comprises a sequence that has one, two, or three differences from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:58, SEQ ID NO:61, SEQ ID NO:118.

[0034] The MAPT RNAi agent described herein may include a modifying agent. The modification may be made to one or more nucleotides of the sense strand and / or antisense strand, or to the internucleotide linkage, which is the bond between two nucleotides in the sense strand or antisense strand. For example, some 2'-modifications of ribose or deoxyribose may increase RNA stability or DNA stability and half-life. Such 2'-modifications may be 2'-fluoro, 2'-O-methyl (i.e., 2'-methoxy), 2'-O-alkyl, such as 2'-O-C16 alkyl modified nucleotides, or 2'-O-methoxyethyl (2'-O-MOE).

[0035] In some embodiments, one or more nucleotides of the sense strand and / or antisense strand are independently modified nucleotides, meaning that the sense strand and the antisense strand can have different modified nucleotides. In some embodiments, one or more nucleotides of the sense strand are modified nucleotides. In some embodiments, each nucleotide of the sense strand is a modified nucleotide. In some embodiments, one or more nucleotides of the antisense strand are modified nucleotides. In some embodiments, each nucleotide of the antisense strand is a modified nucleotide. In some embodiments, the modified nucleotide is a 2'-fluoro modified nucleotide, a 2'-O-methyl modified nucleotide, or a 2'-O-alkyl modified nucleotide, such as a 2'-O-C16 alkyl modified nucleotide. In some embodiments, each nucleotide of the sense strand and the antisense strand is independently modified nucleotide, such as a 2'-fluoro modified nucleotide, a 2'-O-methyl modified nucleotide, or a 2'-O-alkyl modified nucleotide, such as a 2'-O-C16 alkyl modified nucleotide.

[0036] In some embodiments, the sense strand has four 2'-fluoro modified nucleotides, e.g., at positions 7, 9, 10, and 11 from the 5' end of the sense strand. In some embodiments, the nucleotides at positions other than positions 7, 9, 10, and 11 of the sense strand are 2'-O-methyl or 2'-O-C16 alkyl modified nucleotides. In some embodiments, the antisense strand has four 2'-fluoro modified nucleotides, e.g., at positions 2, 6, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the nucleotides at positions other than positions 2, 6, 14, and 16 of the antisense strand are 2'-O-methyl or 2'-O-C16 alkyl modified nucleotides.

[0037] In some embodiments, the sense strand has three 2'-fluoro modified nucleotides, e.g., at positions 9, 10, and 11 from the 5' end of the sense strand. In some embodiments, the other nucleotides of the sense strand are 2'-O-methyl modified nucleotides. In some embodiments, the antisense strand has five 2'-fluoro modified nucleotides, e.g., at positions 2, 5, 7, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the antisense strand has five 2'-fluoro modified nucleotides, e.g., at positions 2, 5, 8, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the antisense strand has five 2'-fluoro modified nucleotides, e.g., at positions 2, 3, 7, 14, and 16 from the 5' end of the antisense strand. In some embodiments, the other nucleotides of the antisense strand are 2'-O-methyl modified nucleotides. In some embodiments, the sense strand comprises an abasic portion or an inverted abasic portion.

[0038] In some embodiments, the modified nucleotide is a 2'-O-alkyl modified nucleotide, such as a 2'-O-C16 alkyl modified nucleotide, which can function as a delivery moiety. In some embodiments, the 2'-O-alkyl modified nucleotide is 2'-O-hexadecyluridine, 2'-O-hexadecycytidine, 2'-O-hexadecyguanine, or 2'-O-hexadecyladenosine. In some embodiments, 2'-O-hexadecyluridine, 2'-O-hexadecycytidine, 2'-O-hexadecyguanine, or 2'-O-hexadecyladenosine is the modified nucleotide in the sense strand.

[0039] In some embodiments, the first nucleotide from the 5' end of the antisense strand is a modified nucleotide having a phosphate analog, such as 5'-vinylphosphonate (5'-VP).

[0040] In some embodiments, the sense strand comprises an abasic portion or an inverted abasic portion, such as those shown in Table 3.

[0041] In some embodiments, the sense strand and the antisense strand have one or more modified internucleotide linkages. In some embodiments, the modified nucleotide linkages are phosphorothioate linkages. In some embodiments, the sense strand has four or five phosphorothioate linkages. In some embodiments, the antisense strand has four or five phosphorothioate linkages. In some embodiments, the sense strand and the antisense strand each have four or five phosphorothioate linkages. In some embodiments, the sense strand has four phosphorothioate linkages and the antisense strand has four phosphorothioate linkages.

[0042] In a further aspect, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:25, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:26; (b) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:27, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:28; (c) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:29, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:30; (d) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:31, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:32; (e) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 33, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 34; (f) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:35, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:36; (g) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:37, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:38; (h) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:39, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:40; (i) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:41, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:42; (j) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:43, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:44; (k) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:45, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:46; (l) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:47, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:48; (m) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:63, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:40; (n) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to any one of SEQ ID NO: 64, SEQ ID NO: 66 to 69, SEQ ID NO: 71, SEQ ID NO: 75 to 86, and SEQ ID NO: 93 to 100, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 65; (o) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 64, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to any one of SEQ ID NO: 70 and SEQ ID NOs: 72 to 74; (p) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:87 or SEQ ID NO:89, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:88; (q) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:90 or SEQ ID NO:92, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:91; (r) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:101, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:102; (s) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 103, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 104; (t) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 105, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to any one of SEQ ID NO: 65 and SEQ ID NOs: 106 to 108; (u) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 109, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO: 65; (v) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:110, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:40; (w) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:111, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:112; (x) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:113, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:114, and (y) a sense strand comprising a first nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:115, and an antisense strand comprising a second nucleic acid sequence having at least 90% (e.g., about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) sequence identity to SEQ ID NO:116. The MAPT RNAi agent comprises a pair of nucleic acid sequences selected from the group consisting of:

[0043] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 63, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (n) a sense strand comprising a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NOs: 66 to 69, SEQ ID NO: 71, SEQ ID NOs: 75 to 86, and SEQ ID NOs: 93 to 100, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 64, and an antisense strand comprising a second nucleic acid sequence selected from any one of SEQ ID NO: 70 and SEQ ID NOs: 72 to 74; (p) a sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 88; (q) a sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 91; (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 101, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 102; (s) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 103, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 104; (t) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand comprising a second nucleic acid sequence selected from SEQ ID NO: 65, and any one of SEQ ID NOs: 106 to 108; (u) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (v) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (w) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:111, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:112; (x) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 114, and (y) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 116. The MAPT RNAi agent comprises a pair of nucleic acid sequences selected from the group consisting of:

[0044] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 25, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 26. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 27, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 28. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 29, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 30. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 31, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 32. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 33, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 34. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 35, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 36.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 37, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 38. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 39, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 40. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 41, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 42. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 43, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 44. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 45, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 46. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 47, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 48.

[0045] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 63, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NO: 66-69, SEQ ID NO: 71, SEQ ID NO: 75-86, and SEQ ID NO: 93-100, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 64, and the antisense strand comprising a second nucleic acid sequence selected from any one of SEQ ID NO: 70, SEQ ID NO: 72 to 74. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 88. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 91.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 101, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 102. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 103, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 104.

[0046] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 105, and the antisense strand comprising a second nucleic acid sequence selected from any one of SEQ ID NO: 65, SEQ ID NO: 106-108. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 109, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 110, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 111, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 112. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 113, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 114. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 115, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 116.

[0047] In some embodiments, a MAPT RNAi agent described herein may comprise a sense strand that comprises a sequence that has one, two, or three differences from SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NOs:66-69, SEQ ID NO:71, SEQ ID NOs:75-87, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NOs:92-101, SEQ ID NO:103, SEQ ID NO:105, SEQ ID NOs:109-111, SEQ ID NO:113, SEQ ID NO:115. In some embodiments, a MAPT RNAi agent described herein may comprise an antisense strand that comprises a sequence that has one, two, or three differences from SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NOs:72-74, SEQ ID NO:88, SEQ ID NO:91, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NOs:106-108, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116.

[0048] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, and the sense strand and the antisense strand are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO: 63, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (n) a sense strand having a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NOs: 66 to 69, SEQ ID NO: 71, SEQ ID NOs: 75 to 86, and SEQ ID NOs: 93 to 100, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 64, and an antisense strand having a second nucleic acid sequence selected from any one of SEQ ID NO: 70 and SEQ ID NOs: 72 to 74; (p) a sense strand having a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 88; (q) a sense strand having a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 91; (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 101, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 102; (s) a sense strand having a first nucleic acid sequence of SEQ ID NO: 103, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 104; (t) a sense strand having a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand having a second nucleic acid sequence selected from SEQ ID NO: 65 and any one of SEQ ID NOs: 106 to 108; (u) a sense strand having a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (v) a sense strand having a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (w) a sense strand having a first nucleic acid sequence of SEQ ID NO:111, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:112; (x) a sense strand having a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 114, and (y) a sense strand having a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 116. The MAPT RNAi agent has a pair of nucleic acid sequences selected from the group consisting of:

[0049] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 25, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 26. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 27, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 28. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 29, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 30. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 31, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 32. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 33, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 34. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 35, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 36.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 37, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 38. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 39, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 40. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 41, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 42. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 43, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 44. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 45, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 46. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 47, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 48.

[0050] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 63, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 40. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NO: 66-69, SEQ ID NO: 71, SEQ ID NO: 75-86, and SEQ ID NO: 93-100, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 65. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 64, and the antisense strand having a second nucleic acid sequence selected from any one of SEQ ID NO: 70, SEQ ID NO: 72 to 74. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 88. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 91.In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 101, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 102. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 103, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 104.

[0051] In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 105, and the antisense strand having a second nucleic acid sequence selected from any one of SEQ ID NO: 65, SEQ ID NO: 106-108. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 109, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 65. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand forming a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 110, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 40. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 111, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 112. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 113, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 114. In some embodiments, provided herein is a MAPT RNAi agent having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, the sense strand having a first nucleic acid sequence of SEQ ID NO: 115, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 116.

[0052] [Table 2-1]

[0053] [Table 2-2]

[0054] [Table 2-3]

[0055] [Table 2-4] Abbreviations - "m" denotes 2'-OMe, "f" denotes 2'-fluoro, * " indicates phosphorothioate linkage, "VP" indicates 5'-vinylphosphonate, "Uhd" indicates 2'-O-hexadecyluridine, "Chd" indicates 2'-O-hexadecylcytidine, "Ahd" indicates 2'-O-hexadecyladenosine, "iAb" indicates an inverted abasic moiety, "n" indicates an abasic moiety, "S" indicates the sense strand, and "AS" indicates the antisense strand.

[0056] [Table 3] "5'" and "3'" indicate the 5' to 3' direction of a sequence.

[0057] In some embodiments, the sense strand of the MAPT RNAi agent has a delivery moiety. In some embodiments, the sense strand of the MAPT RNAi agent has a delivery moiety conjugated to the 5' or 3' end of the sense strand. In some embodiments, the sense strand of the MAPT RNAi agent has a delivery moiety conjugated to a nucleotide of the sense strand. The delivery moiety may facilitate entry of the RNAi agent into a cell. In some embodiments, the delivery moiety is α-tocopherol or palmitic acid (see Table 4). In some embodiments, the delivery moiety is a delivery moiety known for delivering RNAi agents to cells, such as those described in Hu et al., Signal Transduction and Targeted Therapy (2020) 5:101. Placement of the delivery moiety on the RNAi agent is necessary to overcome potential inefficient loading of AGO2 (Argonaute-2) or other impediments to RNA-Induced Silencing Complex (RISC) complex activity.

[0058] In some embodiments, the delivery moiety is conjugated to the 5'-end or 3'-end of the sense strand via a linker. In some embodiments, the linker is selected from linker 1, linker 2, linker 3, or linker 4 in Table 5. Other suitable linkers are well known in the art. Exemplary linker-delivery moiety pairs are shown in Table 6. In some embodiments, the MAPT RNAi agent has a linker-delivery moiety pair in Table 6.

[0059] In some embodiments, the delivery moiety is conjugated to a nucleotide of the sense strand. In that case, the delivery moiety is a modified nucleotide located in the sense strand. In some embodiments, the modified nucleotide is 2'-O-hexadecyluridine, 2'-O-hexadecycytidine, 2'-O-hexadecyguanine, or 2'-O-hexadecyladenosine (Table 4).

[0060] [Table 4-1]

[0061] [Table 4-2]

[0062] [Table 5]

[0063] [Table 6-1]

[0064] [Table 6-2]

[0065] In a further aspect, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a double stranded RNA (dsRNA) having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, and wherein the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand comprising a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 59, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 58; (q) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 118; (t) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16. comprising a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0066] In some embodiments, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a double-stranded RNA (dsRNA) having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, and wherein the sense strand and the antisense strand are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO:1, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:2; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 3, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 4; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO:5, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:6; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 7, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 8; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 9, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 10; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO:11, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:12; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 13, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 14; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 15, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 17, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 18; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 19, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 20; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 21, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 22; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 23, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 24; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO:55, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (n) a sense strand having a first nucleic acid sequence of SEQ ID NO:56, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 57, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 58; (p) a sense strand having a first nucleic acid sequence of SEQ ID NO:59, and an antisense strand having a second nucleic acid sequence of SEQ ID NO:58; (q) a sense strand having a first nucleic acid sequence of SEQ ID NO: 60, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 62, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (s) a sense strand having a first nucleic acid sequence of SEQ ID NO: 117, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 118, and (t) a sense strand having a first nucleic acid sequence of SEQ ID NO: 119, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 16. having a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of the sense strand and the antisense strand are independently modified nucleotides, and optionally, one or more internucleotide linkages of the sense strand and the antisense strand are modified internucleotide linkages.

[0067] In some embodiments, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a double-stranded RNA (dsRNA) having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, and wherein the sense strand and the antisense strand are (a) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand comprising a second nucleic acid sequence selected from SEQ ID NO: 65 and SEQ ID NOs: 106 to 108; (n) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (p) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 111, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 112; (q) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 114, and (r) a sense strand comprising a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 116. The nucleic acid sequence comprises a pair of nucleic acid sequences selected from the group consisting of:

[0068] In some embodiments, provided herein is a MAPT RNAi agent of formula (I): RLD, wherein R is a double-stranded RNA (dsRNA) having a sense strand and an antisense strand, wherein the sense strand and the antisense strand form a duplex, wherein D is a delivery means for delivering the dsRNA to a cell, and L is a linking means for linking the dsRNA to a delivery means or is optionally absent, and wherein the sense strand and the antisense strand are (a) a sense strand having a first nucleic acid sequence of SEQ ID NO: 25, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 26; (b) a sense strand having a first nucleic acid sequence of SEQ ID NO: 27, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 28; (c) a sense strand having a first nucleic acid sequence of SEQ ID NO: 29, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 30; (d) a sense strand having a first nucleic acid sequence of SEQ ID NO: 31, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 32; (e) a sense strand having a first nucleic acid sequence of SEQ ID NO: 33, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 34; (f) a sense strand having a first nucleic acid sequence of SEQ ID NO: 35, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 36; (g) a sense strand having a first nucleic acid sequence of SEQ ID NO: 37, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 38; (h) a sense strand having a first nucleic acid sequence of SEQ ID NO: 39, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (i) a sense strand having a first nucleic acid sequence of SEQ ID NO: 41, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 42; (j) a sense strand having a first nucleic acid sequence of SEQ ID NO: 43, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 44; (k) a sense strand having a first nucleic acid sequence of SEQ ID NO: 45, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 46; (l) a sense strand having a first nucleic acid sequence of SEQ ID NO: 47, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 48; (m) a sense strand having a first nucleic acid sequence of SEQ ID NO: 105, and an antisense strand having a second nucleic acid sequence selected from SEQ ID NO: 65 and SEQ ID NOs: 106 to 108; (n) a sense strand having a first nucleic acid sequence of SEQ ID NO: 109, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (o) a sense strand having a first nucleic acid sequence of SEQ ID NO: 110, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (p) a sense strand having a first nucleic acid sequence of SEQ ID NO: 111, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 112; (q) a sense strand having a first nucleic acid sequence of SEQ ID NO: 113, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 114, and (r) a sense strand having a first nucleic acid sequence of SEQ ID NO: 115, and an antisense strand having a second nucleic acid sequence of SEQ ID NO: 116. The nucleic acid sequence of the present invention is selected from the group consisting of:

[0069] In some embodiments, the delivery means is conjugated to the sense strand. In some embodiments, the delivery means is conjugated to the 5' or 3' end of the sense strand. In some embodiments, the delivery means is conjugated to a nucleotide of the sense strand. In some embodiments, the delivery means is palmitic acid or alpha tocopherol. In some embodiments, the linking means is selected from the group consisting of Linker 1, Linker 2, Linker 3, and Linker 4 of Table 5.

[0070] The sense and antisense strands of MAPT RNAi agents can be synthesized using any nucleic acid polymerization method known in the art, such as solid phase synthesis by using phosphoramidite chemistry methodology (e.g., Current Protocols in Nucleic Acid Chemistry, Beaucage, SL et al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA), H-phosphonate methods, phosphotriester chemistry, or enzymatic synthesis. Automated commercially available synthesizers, such as the MerMade™ 12 from LGC Biosearch Technologies, or the BioAutomation or Applied Biosystems synthesizers, can be used. Other synthesizers from Biosystems may be used. Phosphorothioate linkages may be introduced using sulfurizing agents such as phenylacetyl disulfide or DDTT (((dimethylaminomethylidene)amino)-3H-1,2,4-dithiazoline-3-thione). It is well known to use similar techniques and commercially available modified amidites and Controlled-Pore Glass (CPG) products to synthesize modified and conjugated oligonucleotides.

[0071] Purification methods can be used to eliminate undesired impurities from the final oligonucleotide product. Commonly used purification techniques for single-stranded oligonucleotides include reverse-phase ion pair high performance liquid chromatography (RP-IP-HPLC), capillary gel electrophoresis (CGE), anion exchange HPLC (AX-HPLC), and size exclusion chromatography (SEC). After purification, oligonucleotides can be analyzed by mass spectrometry and quantified by spectrophotometry at a wavelength of 260 nm. Then, sense and antisense strands can be annealed to form a double strand.

[0072] In another aspect, provided herein is a pharmaceutical composition comprising the MAPT RNAi agent described herein and a pharma- ceutically acceptable carrier. Also provided herein is a pharmaceutical composition comprising a means for reducing MAPT expression in a cell and a pharma- ceutically acceptable carrier. Such a pharmaceutical composition may also comprise one or more pharma- ceutically acceptable excipients, diluents, or carriers. The pharmaceutical composition may be prepared by methods well known in the art (e.g., Remington: The Science and Practice of Pharmacy, 23rd edition (2020), A. Loyd et al., Academic Press).

[0073] In a further aspect, a method for reducing MAPT expression in a cell (e.g., a neuronal cell) is provided herein, which may include introducing a MAPT RNAi agent described herein into the cell and incubating the cell for a time sufficient for degradation of MAPT mRNA, thereby reducing MAPT expression in the cell. The MAPT RNAi agent may be introduced into a cell (e.g., a neuronal cell) using methods well known in the art, such as transfection, electroporation, microinjection, or uptake by the cell via natural transport mechanisms.

[0074] In another aspect, the present disclosure provides a method for reducing MAPT expression in a patient in need thereof, comprising administering to the patient an effective amount of MAPT RNAi agent or pharmaceutical composition as described herein. MAPT aggregation can be caused by overexpression of MAPT protein or mutations that affect the structure of the protein, leading to an increased tendency of MAPT protein to self-associate. Therefore, reducing MAPT expression level can be beneficial for patients with tauopathy.

[0075] In another aspect, provided herein is a method of treating a tauopathy in a patient in need thereof, comprising administering to the patient an effective amount of a MAPT RNAi agent or pharmaceutical composition described herein. Exemplary tauopathies include, but are not limited to, Alzheimer's Disease (AD), frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), behavioral variant frontotemporal dementia (bvFTD), nonfluent variant Primary Progressive Aphasia (nfvPPA), Parkinsonism, Pick's disease (PiD), Primary Progressive Aphasia-Semantic (PPA-S), Primary Progressive Aphasia-Logopenic (PPA-L), Multiple System Tauopathy with Dementia (MSD), and / or Multiple System Tauopathy with Dementia (MSD). Presenile Dementia (MSTD), Neurofibrillary Tangle (NFT) Dementia, FTD with Motor Neuron Disease, Progressive Supranuclear Palsy (PSP), Amyotrophic Lateral Sclerosis / Parkinsonism-Dementia Complex (ALS-PDC), Argyrophilic Grain Dementia (AGD), British Amyloid Angiopathy, Cerebral Amyloid Angiopathy, Chronic Traumatic Eencephalopathy (CTE), Corticobasal Degeneration (CBD), Creutzfeldt-Jakob DiseaseCJD, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, epilepsy, Gerstmann-Sträussler-Scheinker syndrome, Hallervorden-Spatz disease, Huntington's disease, inclusion body myositis, lead toxic encephalopathy, Ritiko-Bodig disease (Parkinson-dementia complex syndrome of Guam), meningioangiomatosis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C C, NP-C), non-guanine motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, neurofibrillary tangle senile dementia, neurofibrillary senile dementia, argyrophilic grain disease, ganglioglioma, gangliocytoma, subacute sclerosing panencephalitis, tuberous sclerosis, lipofuscinosis, primary age-related tauopathy (primary age-related tauopathy, PART), globular glial tauopathy (GGT). In some embodiments, the tauopathy is Alzheimer's disease (AD), frontotemporal dementia (FTD), or progressive supranuclear palsy (PSP).

[0076] The MAPT RNAi agent may be administered to the patient via intrathecal, intracerebroventricular, or intracisternal injection. In some embodiments, the MAPT RNAi agent is administered to the patient intrathecally via a catheter.

[0077] RNAi dosing regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.

[0078] Dosage values ​​can vary depending on the type and severity of the condition to be alleviated. It will be further understood that for any particular subject, specific dosage regimens will be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

[0079] In another aspect, provided herein is a MAPT RNAi agent or a pharmaceutical composition comprising a MAPT RNAi agent for use in reducing MAPT expression.Also provided herein is a MAPT RNAi agent or a pharmaceutical composition comprising a MAPT RNAi agent for use in treatment.Also provided herein is a MAPT RNAi agent or a pharmaceutical composition comprising a MAPT RNAi agent for use in treating tauopathy.Also provided herein is the use of a MAPT RNAi agent in the manufacture of a medicament for treating tauopathy.

[0080] As used herein, the terms "a," "an," "the," and similar terms as used in the context of this disclosure (particularly in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise specified herein or clearly contradicted by context.

[0081] As used herein, the term "alkyl" means a saturated linear or branched monovalent hydrocarbon radical containing the indicated number of carbon atoms. For example, "C1-C 20 Alkyl (C1-C 20 "alkyl" means a radical having 1 to 20 carbon atoms in a linear or branched arrangement.

[0082] As used herein, "antisense strand" refers to an oligonucleotide that is complementary to a region of a target sequence. Similarly, as used herein, "sense strand" refers to an oligonucleotide that is complementary to a region of the antisense strand.

[0083] As used herein, "complementary" refers to a structural relationship between two nucleotides (e.g., on two opposing nucleic acids or on opposing regions of a single nucleic acid strand) that allows the two nucleotides to base pair with each other. For example, when a purine nucleotide of one nucleic acid is complementary to a pyrimidine nucleotide of an opposing nucleic acid, they may base pair by forming hydrogen bonds with each other. Complementary nucleotides may base pair in a Watson-Crick manner or in any other manner that allows the formation of a stable duplex. Similarly, two nucleic acids may have regions of multiple nucleotides that are complementary to each other and form a region of complementarity, as described herein.

[0084] As used herein, a "delivery moiety" refers to a chemical moiety that facilitates entry of an oligonucleotide or RNAi agent into a cell. A delivery moiety can be a lipid, cholesterol, vitamin E, carbohydrate, amino sugar, polypeptide, or protein.

[0085] As used herein, "duplex," with respect to a nucleic acid or oligonucleotide, means the structure formed through complementary base pairing of two antiparallel sequences of nucleotides, whether formed by two separate nucleic acid strands or by a single folded strand (e.g., via a hairpin).

[0086] "Effective amount" refers to the amount (duration and means of administration) necessary to achieve the desired therapeutic result. The effective amount of an RNAi agent may vary depending on factors such as the individual's condition, age, sex and weight, and the ability of the RNAi agent to induce a desired response in the individual. An effective amount is also an amount in which any toxic or harmful effects of the RNAi agent are outweighed by the therapeutically beneficial effects.

[0087] The terms "have," "having," or "has," when referring to a sequence, mean consisting of or consisting essentially of.

[0088] The term "knockdown" or "expression knockdown" refers to the reduction of mRNA or protein expression of a gene following treatment with a reagent, e.g., an RNAi agent.

[0089] As used herein, "modified internucleotide linkage" refers to an internucleotide linkage that has one or more chemical modifications when compared to a reference internucleotide linkage that has a phosphodiester bond. Typically, the modified internucleotide linkage confers one or more desirable properties to the nucleic acid in which the modified internucleotide linkage is present. For example, the modified nucleotide may improve thermal stability, resistance to degradation, nuclease resistance, solubility, bioavailability, biological activity, reduced immunogenicity, etc. In some embodiments, the modified internucleotide linkage is a phosphorothioate linkage.

[0090] As used herein, "modified nucleotide" refers to a nucleotide that has one or more chemical modifications when compared to a corresponding reference nucleotide selected from adenine ribonucleotide, guanine ribonucleotide, cytosine ribonucleotide, uracil ribonucleotide, adenine deoxyribonucleotide, guanine deoxyribonucleotide, cytosine deoxyribonucleotide, and thymidine deoxyribonucleotide. The modified nucleotide may have one or more chemical modifications, for example, at its sugar, nucleobase, and / or phosphate group. Additionally or alternatively, the modified nucleotide may have one or more chemical moieties conjugated to the corresponding reference nucleotide. In some embodiments, the modified nucleotide is a 2'-fluoro modified nucleotide, a 2'-O-methyl modified nucleotide, or a 2'-O-alkyl modified nucleotide, for example, a 2'-O-C16 alkyl modified nucleotide. In some embodiments, the modified nucleotide has a phosphate analog, for example, a 5'-vinyl phosphonate. In some embodiments, the modified nucleotide is an abasic moiety or an inverted abasic moiety, for example, a moiety shown in Table 3.

[0091] As used herein, the term "tauopathy" refers to a disease associated with abnormal tau protein expression, secretion, phosphorylation, cleavage, and / or aggregation.

[0092] As used herein, "nucleotide" means an organic compound having a nucleoside (a nucleic acid base (e.g., adenine, cytosine, guanine, thymine, or uracil) and a pentose sugar (e.g., ribose or 2'-deoxyribose)) linked to a phosphate group, which can serve as a monomer unit of nucleic acid polymers (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)).

[0093] As used herein, "oligonucleotide" means a polymer of linked nucleotides, each of which may be modified or unmodified. Oligonucleotides are typically less than about 100 nucleotides in length.

[0094] As used herein, "overhang" refers to an unpaired nucleotide or nucleotides that protrude from the duplex structure of a double-stranded oligonucleotide. An overhang can include one or more unpaired nucleotides that extend from the duplex region at the 5' or 3' end of a double-stranded oligonucleotide. An overhang can be a 3' overhang or a 5' overhang on the antisense or sense strand of a double-stranded oligonucleotide.

[0095] As used herein, the term "patient" refers to a human patient.

[0096] As used herein, "phosphate analog" refers to a chemical moiety that mimics the electrostatic and / or steric properties of a phosphate group. In some embodiments, the phosphate analog is located at the 5'-terminal nucleotide of an oligonucleotide in place of the 5'-phosphate, which is often susceptible to enzymatic removal. The 5' phosphate analog may include a phosphatase-resistant linkage. Examples of phosphate analogs include 5' methylene phosphonate (5'-MP) and 5'-(E)-vinyl phosphonate (5'-VP). In some embodiments, the phosphate analog is 5'-VP.

[0097] The term "% sequence identity" or "percentage sequence identity" with respect to a reference nucleic acid sequence is defined as the percentage of nucleotides, nucleosides, or nucleic acid bases in a candidate sequence that are identical to the nucleotides, nucleosides, or nucleic acid bases in the reference nucleic acid sequence after optimally aligning the sequences and introducing gaps or overhangs, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be accomplished in a variety of ways that are within the skill of the art, for example, using publicly available computer software programs, including those described in Current Protocols in Molecular Biology (Ausubel et al., eds., 1987, Supp. 30, section 7.7.18, Table 7.7.1), such as BLAST, BLAST-2, ALIGN, Clustal W2.0, Clustal X2.0, or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring alignment, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared. The percentage of "sequence identity" can be determined by comparing two optimally aligned sequences over a comparison window, although the fragment of the nucleic acid sequence within the comparison window may contain additions or deletions (e.g., gaps or overhangs) compared to the reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. The percentage can be calculated by calculating the number of positions where the same nucleotide, nucleoside, or nucleic acid base is present in both sequences to determine the number of matched positions, dividing the number of matched positions by the total number of positions within the comparison window, and multiplying the result by 100 to determine the percentage of sequence identity. The output is the percent identity of the subject sequence to the query sequence.

[0098] As used herein, "RNAi", "RNAi agent", "iRNA", "iRNA agent", and "RNA interference agent" refer to an agent that mediates sequence-specific degradation of target mRNA by RNA interference, for example, via the RNA-induced silencing complex (RISC) pathway. In some embodiments, the RNAi agent has a sense strand and an antisense strand, and the sense strand and the antisense strand form a duplex. In some embodiments, the sense strand has a delivery moiety, for example, a delivery moiety conjugated to the 5' or 3' end of the sense strand or to a nucleotide of the sense strand.

[0099] As used herein, a "strand" refers to a single, contiguous sequence of nucleotides linked together by internucleotide linkages (e.g., phosphodiester or phosphorothioate linkages). A strand may have two free ends (e.g., a 5' end and a 3' end).

[0100] As used herein, "MAPT" refers to the human MAPT mRNA transcript, which encodes the microtubule-associated protein tau. The nucleotide sequences of human MAPT transcript variants and the amino acid sequences of human tau protein isoforms can be found below.

[0101] i. MAPT transcript variant 1 → Tau protein isoform 1: NM_016835.5 (nucleotide sequence) → NP_058519.3 (amino acid sequence); ii. MAPT transcript variant 2 → tau protein isoform 2: NM_005910.6 (nucleotide sequence) → NP_005901.2 (amino acid sequence); iii. MAPT transcript variant 3 → tau protein isoform 3: NM_016834.5 (nucleotide sequence) → NP_058518.1 (amino acid sequence); iv. MAPT transcript variant 4 → tau protein isoform 4: NM_016841.5 (nucleotide sequence) → NP_058525.1 (amino acid sequence); v. MAPT transcript variant 5 → tau protein isoform 5: NM_001123067.4 (nucleotide sequence) → NP_001116539.1 (amino acid sequence), vi. MAPT transcript variant 6 → Tau protein isoform 6: NM_001123066.4 (nucleotide sequence) → NP_001116538.2 (amino acid sequence); vii. MAPT transcript variant 7 → Tau protein isoform 7: NM_001203251.2 (nucleotide sequence) → NP_001190180.1 (amino acid sequence); viii. MAPT transcript variant 8 → Tau protein isoform 8: NM_001203252.2 (nucleotide sequence) → NP_001190181.1 (amino acid sequence); ix. MAPT transcript variant 9 → Tau protein isoform 9: NM_001377265.1 (nucleotide sequence) → NP_001364194.1 (amino acid sequence); x. MAPT transcript variant 10 → tau protein isoform 10: NM_001377266.1 (nucleotide sequence) → NP_001364195.1 (amino acid sequence), xi. MAPT transcript variant 11 → Tau protein isoform 11: NM_001377267.1 (nucleotide sequence) → NP_001364196.1 (amino acid sequence); xii. MAPT transcript variant 12 → tau protein isoform 4: NM_001377268.1 (nucleotide sequence) → NP_001364197.1 (amino acid sequence).

[0102] The nucleotide sequence of human MAPT transcript variant 6 (encoding 2N4R tau) can be found in NM_001123066.4.

[0103] JPEG2024545202000012.jpg193151

[0104] JPEG2024545202000013.jpg229151

[0105] JPEG2024545202000014.jpg25150 (sequence number 49).

[0106] The corresponding amino acid sequence of human tau protein isoform 6 can be found in NP_001116538.2:

[0107] JPEG2024545202000015.jpg53148 (sequence number 50).

[0108] The nucleotide sequence of human MAPT transcript variant 5 (encoding 1N4R tau) can be found in NM_001123067.4.

[0109] JPEG2024545202000016.jpg97150

[0110] JPEG2024545202000017.jpg229151

[0111] JPEG2024545202000018.jpg49150 (sequence number 51).

[0112] The corresponding amino acid sequence of human tau protein isoform 5 can be found in NP_001116539.1:

[0113] JPEG2024545202000019.jpg29148 (sequence number 52).

[0114] The nucleotide sequence of human MAPT transcript variant 4 (encoding 0N3R tau) can be found in NM_016841.5.

[0115] JPEG2024545202000020.jpg105150

[0116] JPEG2024545202000021.jpg229151

[0117] JPEG2024545202000022.jpg29150 (sequence number 53).

[0118] The corresponding amino acid sequence of human tau protein isoform 4 can be found in NP_058525.1:

[0119] JPEG2024545202000023.jpg25148 (sequence number 54).

[0120] As used herein, "subject" means a mammal, including a cat, a dog, a mouse, a rat, a chimpanzee, an ape, a monkey, and a human. Preferably, the subject is a human.

[0121] As used herein, "treatment" or "treating" refers to any process that may slow, control, retard or stop the progression of a disorder or disease disclosed herein, or ameliorate the symptoms of the disorder or disease, but does not necessarily indicate the complete elimination of all symptoms of the disorder or disease. Treatment includes the administration of a protein or nucleic acid or vector or composition for the treatment of a disease or condition in a patient, particularly a human. EXAMPLES

[0122] Example 1. Synthesis of Linker-Delivery Moiety Pairs Certain abbreviations are defined as follows: "ACN" refers to acetonitrile, "AEX" refers to anion exchange, "C / D" refers to cleavage and deprotection, "CPG" refers to controlled pore glass, "DCM" refers to dichloromethane, "DEA" refers to diethylamine, "DIEA" refers to N,N-diisopropylethylamine, "DMAP" refers to 4-dimethylaminopyridine, "DMF" refers to dimethylformamide, "DMSO" refers to dimethyl sulfoxide, "DMTCl" refers to 4,4'-dimethoxytrityl chloride, and "DMTCl" refers to 4,4'-dimethoxytrityl chloride. "ES / MS" refers to electrospray mass spectrometry, "EtOAc" refers to ethyl acetate, "EtOH" refers to ethanol and ethyl alcohol, "HBTU" refers to 3-[bis(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexafluorophosphate, "HOBt" refers to 1-hydroxybenzotriazole, "IP-RP" refers to Ion-Pair Reverse Phase, "LCAA CPG" refers to long chain alkylamine controlled pore glass, and "LC / MS" refers to liquid chromatography-mass spectrometry."MWCO" stands for molecular weight cut-off, "NMR" stands for nuclear magnetic resonance, "PBS" stands for phosphate-buffered saline, "PEG" stands for polyethylene glycol, "PVDF" stands for polyvinylidene fluoride, "RP" stands for reverse phase, "RPM" stands for revolutions per minute, and "siRNA" stands for small interfering ribonucleic acid. "TEA" stands for triethylamine, "THF" stands for tetrahydrofuran, "TLC" stands for Thin Layer Chromatography, "TMP" stands for 2,2,6,6-tetramethylpiperidine, "UPLC" stands for Ultra-Performance Liquid Chromatography, and "UV" stands for ultraviolet light.

[0123] [ka]

[0124] Step A of Scheme 1 illustrates the coupling of compound (1) and (2) using a suitable base such as DMAP in a suitable solvent such as DCM to give compound (3). Step B illustrates the coupling of compound (3) with 1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid) in the presence of a base such as potassium carbonate in a solvent system such as water and THF to give compound (4).

[0125] [ka]

[0126] Step A of Scheme 2 shows the Mitsunobu reaction of compound (5) with tert-butyl 1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate using triphenylphosphine and diisopropyl azodicarboxylate in a solvent such as THF to give compound (6). Step B shows the acidic deprotection of compound (6) using an acid such as HCl (hydrochloric acid) in a solvent such as 1,4-dioxane to give compound (7).

[0127] [ka]

[0128] Step A of Scheme 3 shows the protection of compound (8) using DMTCl with a suitable base such as DIEA in a solvent such as DCM to give compound (9). Step B shows the amide coupling of compound (9) with piperidin-4-ylmethanol using HBTU and HOBt with TMP in a solvent such as DCM to give compound (10). Step C shows the deprotection of compound (10) with 20% piperidine in DMF to give compound (11).

[0129] [ka]

[0130] Step A of Scheme 4 shows the amide coupling between compound (11) and either compound (4) or compound (7) using standard coupling reagents such as HBTU and HOBt with a base such as DIEA in a solvent such as DMF to give compound (12). Those skilled in the art will recognize the various conditions that can be used to perform this amide coupling. Step B shows the coupling of compound (12) with succinic anhydride using a base such as TEA and catalytic DMAP in a solvent such as DCM to give compound (13). Step C shows the amide coupling of compound (13) to amino LCAA CPG using HBTU with a base such as DIEA in a solvent such as ACN, followed by a multi-step work-up to give compound (14).

[0131] Preparation 1 2,5-Dioxopyrrolidin-1-ylpalmitic acid

[0132] [ka]

[0133] Palmitic acid (2.00 g, 7.80 mmol) was added to a solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.79 g, 9.36 mmol) and DMAP (0.19 g, 1.56 mmol) in DCM (31 mL). The mixture was stirred at ambient temperature for 5 min, then N-hydroxysuccinimide (0.99 mg, 8.58 mmol) was added and stirred at ambient temperature for 18 h. The resulting crude material was concentrated in vacuo and purified by silica gel flash chromatography eluting with a gradient of 0-80% EtOAc in hexane to give the title compound as a white solid (2.65 g, 96%). 1 H NMR (DMSO-d6) δ2.81(s,4H), 2.66(t,2H), 1.62(m,2H), 1.25(br s,24H), 0.87(t,3H).

[0134] Preparation 2 3-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid

[0135] [ka]

[0136] 1-Amino-3,6,9,12-tetraoxapentadecan-15-oic acid (0.14 mg, 0.53 mmol) was added to a solution of potassium carbonate (0.14 mg, 1.00 mmol) in THF (1 mL) and water (2 mL). 2,5-Dioxopyrrolidin-1-ylpalmitic acid (0.18 mg, 0.51 mmol) was added and the reaction was stirred at ambient temperature for 18 h. The reaction was quenched with water (30 mL) and the pH was adjusted to .about.3 with 1N aqueous hydrochloric acid. A precipitate formed which was collected by vacuum filtration to give the title compound as a white solid (0.19 mg, 74%). ES / MS m / z 504 (M+H).

[0137] Preparation 3 tert-Butyl 3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoate

[0138] [ka]

[0139] (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-ol (3.00 mg, 6.90 mmol), tert-butyl 1-hydroxy-3,6,9,12-tetraoxapentadecan-15-oate (2.50 mg, 7.60 mmol), and triphenylphosphine (2.00 mg, 7.60 mmol) were mixed in THF (28.0 mL) and diisopropyl azodicarboxylate (1.50 mL, 7.60 mmol) was added dropwise over 5 minutes. The mixture was heated at 60° C. for 16 hours. The mixture was cooled to ambient temperature, silica gel was added, and concentrated in vacuo to give an off-white solid. The mixture was purified by flash chromatography on silica gel eluting with 0-40% EtOAc / hexanes to give the title compound as an oil (3.33 g, 66%). 1 H NMR(CDCl3):3.84(s,4H),3.77-3.71(m,13H),2.59(t,J=6.8Hz,2H),2.52(t,J=6.6Hz,2H),2.20-2.20(m,3H),2.15- 2.12(m,3H),2.10(s,3H),1.87-1.73(m,2H),1.58-1.51(m,4H),1.47(s,9H),1.35-1.27(m,21H),0.90-0.86(m,12H).

[0140] Preparation 4 3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoic acid

[0141] [ka]

[0142] tert-Butyl 3-[2-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoate (3.33 mg, 4.53 mmol) was dissolved in 4M HCl in dioxane (22.6 mL, 90.6 mmol) and stirred at ambient temperature for 16 h. The solvent was removed under reduced pressure to give the title compound as an off-white solid (3.08 g, 100%). ES / MS m / z 678.0 (MH).

[0143] Preparation 5 (2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid

[0144] [ka]

[0145] To a stirred solution of (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-propanoic acid (40 g, 0.122 mol) in dry DCM (400 mL) at 0° C. under inert atmosphere, DIEA (64 mL, 0.366 mol) was added. To this mixture, a solution of DMTCl (49.6 g, 0.146 mol) in DCM (200 mL) was slowly added. Allowed to warm to ambient temperature and stirred for 16 h. After this time, the reaction mixture was diluted with water and extracted with DCM. The organics were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude residue was washed with 10% EtOAc / Hexanes and dried under vacuum to give the crude title compound as a light brown solid (62 g, crude). TLC: 5% MeOH / CH2Cl2 (R f :0.5)UV, 254nM.

[0146] Preparation 6 9H-Fluoren-9-ylmethyl N-[(1S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-[4-(hydroxymethyl)-1-piperidyl]-2-oxo-ethyl]carbamate

[0147] [ka]

[0148] To a stirred solution of (2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid (62 mg, 0.103 mol) in DCM (750 mL) was slowly added HBTU (78.3 mg, 0.206 mol), HOBt (27.9 mg, 0.206 mol), and piperidin-4-ylmethanol (15.4 mg, 0.134 mol) followed by TMP (15 mL, 0.113 mol) under inert atmosphere at 0° C. The resulting reaction mixture was allowed to warm to ambient temperature and stirred for 4 h. After this time, the mixture was diluted with water and extracted with DCM. The organics were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel flash chromatography eluting with 20-40% EtOAc / Hexanes and 1% MeOH / DCM to give the title compound (40 g, 52% over two steps). 1 H NMR (DMSO-d6) δ7.88(br d, J=7.5Hz, 2H), 7.79-7.59(m, 3H), 7.45-7.12(m, 13H), 6.92-6.76(m, 4H), 4.79-4.44(m, 2H), 4.32(br d.

[0149] Preparation 7 (2S)-2-Amino-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-1-[4-(hydroxymethyl)-1-piperidyl]propan-1-one

[0150] [ka]

[0151] A solution of 20% piperidine in DMF (400 mL) is slowly added to 9H-fluoren-9-ylmethyl N-[(1S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-[4-(hydroxymethyl)-1-piperidyl]-2-oxo-ethyl]carbamate (40 g, 0.055 mol) under inert atmosphere at 0° C. The mixture is allowed to warm to ambient temperature and stirred for 1 h. After this time, the mixture is diluted with water and extracted with EtOAc. The organics are dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue is purified by silica gel flash chromatography eluting with 1-8% MeOH / DCM to give the title compound as an off-white solid (13 g, 47%). ES / MS m / z 1009.5 (2M+H).

[0152] Preparation 8 N-[2-[2-[2-[2-[3-[[(1S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-[4-(hydroxymethyl)-1-piperidyl]-2-oxo-ethyl]amino]-3-oxo-propoxy]ethoxy]ethoxy]ethoxy]ethyl]hexadecanamide

[0153] [ka]

[0154] 3-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid (496 mg, 0.984 mmol), HOBt (146 mg, 1.08 mmol), HBTU (410 mg, 1.08 mmol), and DIEA (1.03 mL, 5.90 mmol) were mixed in DMF (9.84 mL) and stirred at ambient temperature for 10 min. (2S)-2-amino-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-1-[4-(hydroxymethyl)-1-piperidyl]propan-1-one (546 mg, 1.08 mmol) was added to the mixture and stirred at ambient temperature for 16 h. The mixture was partitioned between EtOAc and saturated aqueous sodium chloride. The layers were separated and the organics were washed with saturated aqueous sodium chloride. The organics were dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel flash chromatography eluting with 0-10% MeOH / DCM to give the title compound as an oil (327 mg, 34%). 1H NMR (DMSO-d6) 8.21 (d, J = 8.5 Hz, 1H), 7.80 (t, J = 5.6 Hz, 1H), 7.37-7.28 (m, 4H), 7.23-7.20 (m, 5H), 6.88 (d, J = 8.3 Hz, 4H), 5.06-5.02 (m, 1H), 4.51-4.49 (m, 1H), 4.45-4.40 (m, 1H), 3.97-3.93 (m, 1H), 3.74 (s, 5H), 3.63-3.56 (m, 2H). ,3.49-3.48(m,4H),3.47-3.45(m,7H),3.40-3.35(m,2H),3.30(s,1H),3.23-3.13(m,7H),2.41-2.33(m,2H),2.04 (t,J=7.4Hz,2H),1.74-1.69(m,3H),1.51-1.44(m,2H),1.26-1.24(m,24H),1.00-0.97(m,1H),0.88-0.82(m,5H).

[0155] Preparation 9 4-[[1-[(2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-[3-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propanoyl]-4-piperidyl]methoxy]-4-oxo-butanoic acid

[0156] [ka]

[0157] N-[2-[2-[2-[2-[3-[[(1S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-[4-(hydroxymethyl)-1-piperidyl]-2-oxo-ethyl]amino]-3-oxo-propoxy]ethoxy]ethoxy]ethoxy]ethyl]hexadecanamide (320 mg, 0.323 mmol), DMAP (120 mg, 0.969 mmol), TEA (225 μL, 1.62 mmol), and succinic anhydride (64.7 mg, 0.646 mmol) in DCM (6.46 mL) were mixed and the mixture was stirred at ambient temperature for 16 h. The mixture was directly purified by silica gel flash chromatography eluting with 0% to 40% MeOH / DCM to give the title compound as an oil (279 mg, 79%). 1 H NMR(DMSO-d6)12.65-12.64(m,1H),8.24-8.19(m,1H),7.80(t,J=5.6Hz,1H),7.37-7.28(m,4H),7.2 4-7.20(m,5H),6.88(d,J=8.6Hz,4H),5.05-5.01(m,1H),4.44-4.40(m,1H),3.97-3.95(m,3H),3.74( s,6H),3.61-3.56(m,2H),3.49-3.45(m,11H),3.38(t,J=5.9Hz,3H),3.22-3.14(m,6H),2.48-2.31( m,7H),2.04(t,J=7.4Hz,2H),1.90-1.87(m,5H),1.24(s,23H),0.98-0.96(m,1H),0.87-0.82(m,4H).

[0158] Preparation 10 4-[[1-[(2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-[3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propanoyl]-4-piperidyl]methoxy]-4-oxo-butanoic acid

[0159] [ka]

[0160] 3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoic acid (1.20 g, 1.80 mmol), HOBt (260 mg, 1.90 mmol), HBTU (740 mg, 1.90 mmol), and DIEA (1.80 mL, 11.0 mmol) were mixed in DMF (18.0 mL) and stirred at ambient temperature for 10 minutes. (2S)-2-amino-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-1-[4-(hydroxymethyl)-1-piperidyl]propan-1-one (980 mg, 1.90 mmol) was added to the mixture and stirred at ambient temperature for 16 hours. The mixture was partitioned between EtOAc and saturated aqueous sodium chloride. The layers were separated and the organics were washed with saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel flash chromatography eluting with 0-10% MeOH / DCM to give N-[(1S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-[4-(hydroxymethyl)-1-piperidyl]-2-oxo-ethyl]-3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propenamide as a yellow oil.

[0161] A mixture of N-[(1S)-1-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-2-[4-(hydroxymethyl)-1-piperidyl]-2-oxo-ethyl]-3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propenamide (1.45 g, 1.24 mmol), DMAP (456 mg, 3.73 mmol), TEA (867 μL, 6.22 mmol), and succinic anhydride (249 mg, 2.49 mmol) in DCM (24.9) was stirred at ambient temperature for 16 h. The resulting residue was concentrated in vacuo and purified by silica gel flash chromatography eluting with 0-40% MeOH / DCM to give the title compound as an oil (1.36 g, 60%): ES / MS m / z 1264.4 (MH).

[0162] Preparation 11 [4-[[1-[(2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-[3-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propanoyl]-4-piperidyl]methoxy]-4-oxo-butanoyl]amino] on CPG

[0163] [ka]

[0164] 4-[[1-[(2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-[3-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propanoyl]-4-piperidyl]methoxy]-4-oxo-butanoic acid (270 mg, 0.248 mmol) was dissolved in ACN (12.5 mL) and the solution was transferred to a fritted glass dropping funnel. DIEA (150 μL, 0.860 mmol) and HBTU (190 mg, 0.500 mmol) were added to the solution and the mixture was shaken at ambient temperature for 10 minutes. Natural amino LCAA CPG 500 Å (1.92 g, 129 μmol / g) was added to the solution and the mixture was shaken at 500 RPM for 16 hours at ambient temperature. The CPG was drained and dried under nitrogen for 5 min. The CPG was washed with DCM (50 mL), 10% MeOH / DCM (50 mL), then diethyl ether (50 mL). The CPG was dried under nitrogen for 30 min and then resuspended in pyridine (15 mL). Acetic anhydride (3.30 mL, 35.0 mmol) and TEA (0.50 mL) were added and the mixture was shaken at 500 RPM for 2 h at ambient temperature. The CPG was drained and dried under nitrogen for 5 min. The CPG was washed with DCM (50 mL), 10% MeOH / DCM (50 mL), then diethyl ether (50 mL). The CPG was dried under nitrogen for 45 min and the ligand loading was determined at 505 nm to give the title compound (1.92 mg, 75.5 μmol / g).

[0165] Preparation 12 [4-[[1-[(2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-[3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propanoyl]-4-piperidyl]methoxy]-4-oxo-butanoyl]amino] on CPG

[0166] [ka]

[0167] The title compound was prepared from 4-[[1-[(2S)-3-[bis(4-methoxyphenyl)-phenyl-methoxy]-2-[3-[2-[2-[2-[2-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxyethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]propanoyl]-4-piperidyl]methoxy]-4-oxo-butanoic acid in a manner essentially similar to preparation 11. The ligand loading was determined at 505 nm to give the title compound (4.01 g, 66.9 μmol / g).

[0168] Preparation 13 3-[[(2R,3R,4R,5R)-2-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-hexadecoxy-5-(2-hydroxy-4-oxo-pyrimidin-1-yl)THF-3-yl]oxy-(diisopropylamino)phosphanyl]oxypropanenitrile

[0169] [ka]

[0170] The title compound was prepared according to the protocol described in WO2019217459. 1 H NMR(CD3CN):7.86-7.73(m,1H),7.51-7.43(m,2H),7.40-7.23(m,7H),6.95-6.87( m,4H),5.90-5.84(m,1H),5.29-5.21(m,1H),4.54-4.40(m,1H),4.21-4.13(m,1H), 4.10-3.56(m,13H),3.50-3.34(m,2H),2.75-2.62(m,1H),2.55(t,J=6.0Hz,1H),1 .66-1.51(m,2H),1.40-1.14(m,35H),1.08(d,J=6.8Hz,3H),0.91(t,J=6.8Hz,3H). 31P NMR(CD3CN): 149.6, 149.2.

[0171] Preparation 14 N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-hexadecoxyl-tetrahydrofuran-2-yl]purin-6-yl]benzamide

[0172] [ka]

[0173] The title compound was prepared according to the protocol described in WO2019217459. 1 H-NMR(CD3CN)δ9.37(s,1H),8.57(d,J=9.4Hz,1H),8.27(d,J=10.3Hz,1H),7.99(d,J=7.6Hz,2H),7.61( d,J=7.4Hz,1H),7.52(t,J=7.6Hz,2H),7.42(t,J=7.3Hz,2H),7.34-7.16(m,7H),6.85-6.77(m,4H),6.1 1(dd,J=5.0,2.5Hz,1H),4.80(m,1H),4.69(m,1H),4.32(m,1H),3.97-3.78(m,1H),3.74(d,J=3.1Hz,7H),3.64(m,4H),3.56-3.40(m,2H), 3.33(m,1H),2.73-2.59(m,1H),2.50(t,J=6.0Hz,1H),1.52-1.45(m,2H),1.33-1.12(m,37H),1.09(d,J=6.8Hz,3H),0.87(t,J=6.8Hz,3H). 31 P NMR (CD3CN) δ151.19, 150.78.

[0174] Preparation 15 N-[1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-hexadecoxy-tetrahydrofuran-2-yl]-2-oxo-pyrimidin-4-yl]acetamide

[0175] [ka]

[0176] The title compound was prepared according to the protocol described in WO2019217459. 1 H-NMR(CD3CN)9.15(s,1H),8.46(dd,J=7.5Hz,1H),7.95(d,J=7.6Hz,2H),7.63(t,J=7.5Hz,1H),7.57-7.41(m,5H),7.41-7. 31(m,6H),7.28(m,1H),7.04(d,J=15.8Hz,1H),6.90(t,J=7.9Hz,4H),5.90(d,J=7.8Hz,1H),4.51(m,1H),4.20(dd,J=10.6,8 .1Hz,1H),4.04(dd,J=31.3,4.6Hz,1H),3.91-3.81(m,2H),3.79(d,J=3.1Hz,6H),3.74(m,2H),3.69-3.41(m,6H),2.67-2.59 (m,1H),2.54-2.48(m,1H),1.58(m,2H),1.36(m,2H),1.25(d,J=4.7Hz,26H),1.21-1.09(m,10H),1.04(d,J=6.8Hz,3H),0.87 (t,J=6.8Hz,3H). 31 P NMR(CD3CN)δ151.10,150.19.

[0177] Preparation 16 N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenyl-methoxy]methyl]-4-[2-cyanoethoxy-(diisopropylamino)phosphanyl]oxy-3-hexadecoxyl-tetrahydrofuran-2-yl]-6-oxo-1H-purin-2-yl]-2-methyl-propanamide

[0178] [ka]

[0179] The title compound was prepared according to the protocol described in WO2019217459. 1 H-NMR(CDCl3)δ12.01-11.96(m,1H),7.82-7.78(m,1H),7.59-7.53(m,1H),7.47-7.42(m,1H),7.41-7.37(m, 2H),7.34-7.29(m,2H),7.27-7.22(m,3H),6.85-6.80(m,4H),5.99-5.82(m,1H),4.40-4.36(m,1H),4.17-4. 11(m,1H),3.80-3.77(m,6H),3.76-3.68(m,6H),3.22-3.17(m,1H),2.84-2.79(m,1H),1.60-1.54(m,4H),1. 35-1.30(m,6H),1.27(s,19H),1.24-1.15(m,13H),1.06-1.03(m,5H),0.93-0.88(m,6H),0.74-0.70(m,1H). 31 P NMR(CDCl3)δ150.20, 149.92.

[0180] Example 2. Synthesis of MAPT RNAi Agent Single strands (sense and antisense) of the RNA duplex were synthesized on a solid support via MerMade™ 12 (LGC Biosearch Technologies). The sequences of the sense and antisense strands are shown in Table 2. Oligonucleotides were synthesized via phosphoramidite chemistry at either 5, 10, 25 or 50 μmol scale.

[0181] For the sense strand, the type of solid support was Universal CPG: (3'-piperidinol-PEG-palmitic acid) and (3'-piperidinol-PEG-tocopherol) were synthesized in-house (see Example 1), while Universal UnyLinker (Chemgenes, Cat. No. AT273-27) and 3'Teg-Tocopherol (LGC Biosearch Technologies, Cat. No. BG7-1190) were purchased commercially. For all antisense strands, commercially available standard supports mA were utilized. Standard reagents were used for oligo synthesis (Table 7), where 0.1 M hydrogenated xanthan in pyridine was used as the sulfurizing reagent and 20% DEA in ACN was used as the post-synthesis auxiliary wash. All monomers (Table 8) were made up at 0.1 M in ACN and contained a molecular sieves trap bag.

[0182] Oligonucleotides were cleaved and deprotected (C / D) at 45°C for 20 hours. The sense strand was C / Ded from the CPG using ammonia hydroxide (28-30%, cold), while 3% DEA in ammonia hydroxide (28-30%, cold) was used for the antisense strand. C / D was determined to be complete by IP-RP LCMS when the mass data obtained confirmed sequence identity. Depending on scale, the CPG was filtered through a 0.45um PVDF syringeless filter, a 0.22um PVDF Steriflip® vacuum filtration, or a 0.22um PVDF Stericup® Quick release. The CPG was backwashed / rinsed with either 30% ACN / RNase free water or 30% EtOH / RNase free water, then filtered through the same filtration device and combined with the first filtrate. This was repeated twice. The material was then divided equally into 50 mL Falcon tubes and the organics removed via Genevac™. After concentration, it was diluted back to synthesis scale with RNase-free water and the crude oligonucleotides were filtered through either a 0.45 μm PVDF syringeless filter, a 0.22 μm PVDF Steriflip® vacuum filtration, or a 0.22 μm PVDF Stericup® Quick release.

[0183] Crude oligonucleotides were purified via the AKTA™ Pure purification system using either anion exchange (AEX) or reversed phase (RP) Source 15Q-RP columns. For AEX, it was an ES Industry Source™ 15Q column with MPA: 20 mM NaH2PO4, 15% ACN, pH 7.4, and MPB: 20 ​​mM NaH2PO4, 1 M NaBr, 15% ACN, pH 7.4, with the column temperature maintained at 65°C. For RP, it was a Source™ 15Q-RP column with MPA: 50 mM NaOAc with 10% ACN, and MPB: 50 mM NaOAc with 80% ACN. In all cases, fractions containing greater than 85% mass purity and not containing >5% impurities were combined.

[0184] The purified oligonucleotides were desalted using 15mL 3K MWCO centrifuge spin tubes at 3500xg for approximately 30 minutes. The oligonucleotides were rinsed with RNase-free water until the conductivity of the eluate reached <100 usemi / cm. After desalting was complete, 2-3mL of RNase-free water was added, then aspirated 10 times and the retention was transferred to a 50mL Falcon tube, which was repeated until complete transfer of the oligos by measuring the concentration of the compounds on the filter via a nanodrop. The final oligonucleotides were then nanofiltered twice via 15mL 100K MWCO centrifuge spin tubes at 3500xg for 2 minutes. The final desalted oligonucleotides were analyzed for concentration (nanodrop at A260) and characterized by IP-RP LCMS for mass purity and UPLC for UV purity.

[0185] For preparation of duplex, equimolar amounts of sense and antisense strands were combined and heated at 65°C for 10 minutes, then slowly cooled to ambient temperature over 40 minutes. The integrity of duplex was confirmed by UPLC analysis and characterized by LCMS using IP-RP. All duplexes were nanofiltered, and endotoxin levels were then measured by Charles River Endosafe Cartridge Device to obtain the final compound of conjugated RNAi (Table 9). For in vivo analysis, appropriate amounts of duplexes were lyophilized and then reconstituted in 1x PBS for rodent studies and in CSF for non-human primate studies.

[0186] [Table 7]

[0187] [Table 8]

[0188] [Table 9-1]

[0189] [Table 9-2]

[0190] [Table 9-3]

[0191] [Table 9-4] "S" refers to the sense strand and "AS" refers to the antisense strand. * LDP1 is linked 3' to the sense strand. ** LDP4-7 are Uhd, Ahd, Chd, and Ghd linked to nucleotides in the sense strand, respectively.

[0192] Example 3. Characterization of MAPT RNAi agents Selected MAPT RNAi agents were tested in vitro for MAPT inhibition in cultured cells including SH-SY5Y cells, Mouse Cortical Neurons (MCN), and / or human induced pluripotent stem cells (human iPS cells, hiPSC). A subset of selected MAPT RNAi agents was tested in vivo in transgenic human tau mice.

[0193] Materials and Methods SH-SY5Y cell culture and RNAi treatment and analysis: SH-SY5Y cells (ATCC CRL-2266) were derived from the SK-N-SH neuroblastoma cell line (Ross, RA, et al., 1983. J Natl Cancer Inst 71, 741-747). Basal medium consisted of a 1:1 mixture of ATCC formulated Eagle's Minimum Essential Medium (catalogue no. 30-2003) and F12 medium. Complete growth medium was supplemented with 10% fetal bovine serum, 1x amino acids, 1x sodium bicarbonate, and 1x penicillin-streptomycin (Gibco), and cells were incubated at 37°C in a humidified atmosphere of 5% CO2. On day 1, SH-SY5Y cells were seeded into 96-well fibronectin-coated tissue culture plates and allowed to attach overnight. On day 2, complete medium was removed and replaced with RNAi agent in serum-free medium. Cells were incubated with RNAi agents for 72 hours and then gene expression was analyzed. Analysis of gene expression changes in RNAi-treated SH-SY5Y cells was performed using Cells-to-C following the manufacturer's protocol (ThermoFisher A35377). T The expression assays were measured using a kit. Predesigned gene expression assays (supplied as a 20x mixture) were selected from Applied Bio-systems (Foster City, CA, USA). The efficiency of these assays (Thermo Fisher Hs00902194_m1 MAPT and Thermo Fisher Hs99999905_m1 GAPDH) was characterized using a dilution series of cDNA. RT-QPCR was performed in MicroAmp Optical 384-well reaction plates using a QuantStudio 7 Flex system. Relative amounts of gene expression were determined using the delta-delta CT method normalizing to the housekeeping gene GAPDH. IC50 was determined using GraphPad Prism v9.0 with a 4-parameter logistic fit.

[0194] Mouse primary cortical neuron (MCN) culture and RNAi treatment and analysis: Mouse primary cortical neuron cells were isolated from hTau C57BL6 transgenic mouse embryos expressing human tau transgene at E18. Cells were seeded at a density of 40k cells / well in poly-D-lysine coated 96-well plates and cultured in NbActiv1 (BrainBits LLC) containing 1% antibiotic / antimycotic (Corning) in a tissue culture incubator in a humidified chamber with 5% CO2 for 7 days at 37°C. On day 7, half of the medium was removed from each well and 2x concentration of RNAi in culture medium with 2% FBS was added for treatment as CRC and incubated with the cells for another 7, 14 or 21 days. Half of the medium was replaced with fresh culture medium every 7 days. At the end of RNAi treatment, RT-qPCR was performed to quantify MAPT mRNA levels using the TaqMan Fast Advanced Cell-to-CT kit. Specifically, cells were lysed, cDNA was generated using a Mastercycler X50a (Eppendorf), and qPCR was performed using a QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). Human MAPT (Thermo Fisher, Hs00902194_m1) gene expression levels were normalized by β-actin (Thermo Fisher, Mm02619580_g1) using the respective probes.

[0195] Human Induced Pluripotent Stem Cell-derived Neuron (hiPSC) Culture and RNAi Treatment and Analysis: Doxycycline-inducible Neurogenin2 (NGN2) human induced pluripotent stem cells (hiPSCs) were developed by Eli Lilly Bioneer. hiPSCs were doxycycline-induced for 3 days (DIV3) to initiate neuronal differentiation, seeded at 30k / well on 96-well PDL and laminin-coated plates, and grown in Neuronal Differentiation Media (NDM) consisting of DMEM / F12 (Life Technologies, 11330-057), Neurobasal medium (Gibco 15240062), antibiotics, supplements, growth factors, and doxycycline in an incubator (37°C / 5% CO2). Cells were half-fed every 7 days and treated with RNAi on DIV21 by serially diluting the RNAi agent in NDM, aspirating 75 μL according to the dilution, and adding 75 μL of 2x RNAi concentration for a final 1xRNAi. After treatment, cells were half-fed every 7 days by removing half the medium and adding back fresh NDM. Cell lysates were harvested on DIV35 (after 14 days) or DIV42 (after 21 days) and analyzed using TaqMan Fast Advanced Cells-to-C. T RT-qPCR was performed using a PCR kit (Thermo Fisher, A35377) and mRNA knockdown was determined using a MAPT probe (Thermo Fisher, Hs00902194_m1) as the gene of interest and an ACTb probe (Thermo Fisher, Hs99999903_m1) as the housekeeping gene.

[0196] In vivo characterization of selected RNAi agents in transgenic mice The efficacy of selected RNAi agents was also studied in hTau transgenic mice expressing human MAPT RNA and lacking mouse MAPT RNA (Andorfer et al., J Neurochem 2003, 86, 582-590). Six mice were given an intracerebroventricular (ICV) injection of 100 μg of RNAi agent or PBS (phosphate buffered saline) and sacrificed 14 days after injection. MAPT mRNA expression in the brain was measured and analyzed by quantitative PCR (qPCR).

[0197] result Table 10A summarizes the in vitro and in vivo activities of selected MAPT RNAi agents. As shown in Table 10A, the tested RNAi agents knock down MAPT expression in vitro and in vivo.

[0198] [Table 10] * NE means that no effect was observed.

[0199] Additional RNAi agents with different modification patterns were also tested. Table 10B shows the in vitro and in vivo activity of additional MAPT RNAi agents with different modification patterns.

[0200] [Table 11-1]

[0201] [Table 11-2] * ND means not decided.

[0202] Example 4. Knockdown of MAPT mRNA in cynomolgus monkeys after a single dose of MAPT siRNA via intrathecal injection In vivo testing of MAPT RNAi Agent No. 31 (sense strand of SEQ ID NO: 63 and antisense strand of SEQ ID NO: 40) in cynomolgus monkeys (Macaca fascicularis) was performed to evaluate the efficacy of MAPT siRNA. To elucidate the efficacy of siRNA in silencing the target gene, n=4 / group of cynomolgus monkeys were implanted with an indwelling catheter in the lumbar region. Monkeys were infused with either aCSF or MAPT RNAi Agent No. 31 (2.4 mg / ml in aCSF) over 15 minutes and perfused 78 days later. Tissues harvested at necropsy included the spinal cord (lumbar spine) and brain (prefrontal cortex, motor cortex, parietal cortex, hippocampus, and thalamus). qPCR and ELISA were performed to determine MAPT mRNA and protein knockdown, respectively, in central nervous system (CNS) regions. Tables 11 and 12 below show the MAPT mRNA and protein knockdown observed in all regions 78 days after a single administration of siRNA.

[0203] [Table 12]

[0204] [Table 13]

[0205] [Table 14-1]

[0206] [Table 14-2]

[0207] [Table 14-3]

[0208] [Table 14-4]

[0209]

Table 14-5

[0210]

Table 14-6

[0211]

Table 14-7

[0212]

Table 14-8

[0213]

Table 14-9

Claims

1. A MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand form a duplex, The sense strand and the antisense strand are (a) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 15, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 16; (b) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:1, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:2; (c) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:3, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:4; (d) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:5, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:6; (e) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:7, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:8; (f) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:9, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:10; (g) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:11, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:12; (h) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 13, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 14; (i) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 17, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 18; (j) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 19, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 20; (k) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:21, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:22; (l) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:23, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:24; (m) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:55, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:16; (n) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:56, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:16; (o) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:57, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:58; (p) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:59, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:58; (q) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:60, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:61; (r) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:62, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:61; (s) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 117, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 118; and (t) the sense strand comprising a first nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 119, and the antisense strand comprising a second nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:

16. comprising a pair of nucleic acid sequences selected from the group consisting of: Optionally, one or more nucleotides of said sense strand and said antisense strand are independently modified nucleotides, and optionally one or more internucleotide linkages of said sense strand and said antisense strand are modified internucleotide linkages.

2. The sense strand and the antisense strand are (a) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 15, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 16; (b) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:1, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:2; (c) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 3, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 4; (d) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:5, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:6; (e) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 7, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 8; (f) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 9, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 10; (g) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:11, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:12; (h) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 13, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 14; (i) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 17, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 18; (j) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 19, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 20; (k) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:21, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:22; (l) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 23, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 24; (m) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:55, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (n) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:56, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:16; (o) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:57, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:58; (p) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:59, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:58; (q) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 60, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 61; (r) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:62, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:61; (s) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 117, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 118; and (t) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 119, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:

16.

2. The MAPT RNAi agent of claim 1, comprising a pair of nucleic acid sequences selected from the group consisting of:

3. The sense strand and the antisense strand are (a) the sense strand having a first nucleic acid sequence of SEQ ID NO: 15, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 16; (b) the sense strand having a first nucleic acid sequence of SEQ ID NO:1, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:2; (c) the sense strand having a first nucleic acid sequence of SEQ ID NO:3, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:4; (d) the sense strand having a first nucleic acid sequence of SEQ ID NO:5, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:6; (e) the sense strand having a first nucleic acid sequence of SEQ ID NO: 7, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 8; (f) the sense strand having a first nucleic acid sequence of SEQ ID NO: 9, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 10; (g) the sense strand having a first nucleic acid sequence of SEQ ID NO:11, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:12; (h) the sense strand having a first nucleic acid sequence of SEQ ID NO: 13, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 14; (i) the sense strand having a first nucleic acid sequence of SEQ ID NO: 17, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 18; (j) the sense strand having a first nucleic acid sequence of SEQ ID NO: 19, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 20; (k) the sense strand having a first nucleic acid sequence of SEQ ID NO:21, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:22; (l) the sense strand having a first nucleic acid sequence of SEQ ID NO:23, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:24; (m) the sense strand having a first nucleic acid sequence of SEQ ID NO:55, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (n) the sense strand having a first nucleic acid sequence of SEQ ID NO:56, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:16; (o) the sense strand having a first nucleic acid sequence of SEQ ID NO:57, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:58; (p) the sense strand having a first nucleic acid sequence of SEQ ID NO:59, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:58; (q) the sense strand having a first nucleic acid sequence of SEQ ID NO: 60, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 61; (r) the sense strand having a first nucleic acid sequence of SEQ ID NO:62, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:61; (s) the sense strand having a first nucleic acid sequence of SEQ ID NO: 117, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 118; and (t) the sense strand having a first nucleic acid sequence of SEQ ID NO: 119, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:

16. The MAPT RNAi agent of claim 1 or 2, having a pair of nucleic acid sequences selected from the group consisting of:

4. The MAPT RNAi agent of any one of claims 1 to 3, wherein one or more nucleotides of the sense strand are modified nucleotides.

5. The MAPT RNAi agent of any one of claims 1 to 4, wherein each nucleotide of the sense strand is a modified nucleotide.

6. The MAPT RNAi agent of any one of claims 1 to 5, wherein one or more nucleotides of the antisense strand are modified nucleotides.

7. The MAPT RNAi agent of any one of claims 1 to 6, wherein each nucleotide of the antisense strand is a modified nucleotide.

8. The MAPT RNAi agent of any one of claims 1 to 7, wherein the modified nucleotide is a 2'-fluoro modified nucleotide, a 2'-O-methyl modified nucleotide, or a 2'-O-C16 alkyl modified nucleotide.

9. The MAPT RNAi agent of any one of claims 1 to 8, wherein the sense strand has four 2'-fluoro modified nucleotides at positions 7, 9, 10, and 11 from the 5' end of the sense strand.

10. The MAPT RNAi agent of claim 9, wherein the nucleotides at positions other than 7, 9, 10, and 11 of the sense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides.

11. The MAPT RNAi agent of any one of claims 8 to 10, wherein the antisense strand has four 2'-fluoro modified nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand.

12. The MAPT RNAi agent of claim 11, wherein the nucleotides at positions other than 2, 6, 14, and 16 of the antisense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides.

13. 9. The MAPT RNAi agent of any one of claims 1 to 8, wherein the sense strand has three 2'-fluoro modified nucleotides at positions 9, 10, and 11 from the 5' end of the sense strand.

14. The MAPT RNAi agent of claim 13, wherein the nucleotides at positions other than 9, 10, and 11 of the sense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides.

15. 15. The MAPT RNAi agent of any one of claims 1 to 8, 13, 14, wherein the antisense strand has five 2'-fluoro modified nucleotides at positions 2, 5, 7, 14, and 16 from the 5' end of the antisense strand.

16. 16. The MAPT RNAi agent of claim 15, wherein the nucleotides at positions other than 2, 5, 7, 14, and 16 of the antisense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides.

17. The MAPT RNAi agent of any one of claims 1 to 8, 13, 14, wherein the antisense strand has five 2'-fluoro modified nucleotides at positions 2, 5, 8, 14, and 16 from the 5' end of the antisense strand.

18. 18. The MAPT RNAi agent of claim 17, wherein the nucleotides at positions other than 2, 5, 8, 14, and 16 of the antisense strand are 2'-O-methyl modified nucleotides or 2'-O-C16 alkyl modified nucleotides.

19. 19. The MAPT RNAi agent of any one of claims 1-18, wherein the sense strand and the antisense strand have one or more modified internucleotide linkages.

20. 20. The MAPT RNAi agent of claim 19, wherein the modified internucleotide linkage is a phosphorothioate linkage.

21. 21. The MAPT RNAi agent of claim 20, wherein the sense strand has four or five phosphorothioate linkages.

22. 22. The MAPT RNAi agent of claim 20 or 21, wherein the antisense strand has four or five phosphorothioate linkages.

23. The MAPT RNAi agent of any one of claims 1 to 22, wherein the first nucleotide from the 5' end of the antisense strand is a modified nucleotide having a phosphate analog.

24. 24. The MAPT RNAi agent of claim 23, wherein said phosphate analog is a 5'-vinylphosphonate.

25. The MAPT RNAi agent of any one of claims 1 to 24, wherein the sense strand comprises an abasic portion or an inverted abasic portion.

26. A MAPT RNAi agent having a sense strand and an antisense strand, the sense strand and the antisense strand form a duplex, The sense strand and the antisense strand are (a) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 63, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 40; (b) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:25, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:26; (c) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:27, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:28; (d) the sense strand comprising a first nucleic acid sequence of SEQ ID NO:29, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:30; (e) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 31, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 32; (f) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 33, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 34; (g) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 35, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 36; (h) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 37, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 38; (i) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 39, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 40; (j) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 41, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 42; (k) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 43, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 44; (l) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 45, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 46; (m) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 47, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 48; (n) the sense strand comprising a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NO: 66-69, SEQ ID NO: 71, SEQ ID NO: 75-86, and SEQ ID NO: 93-100, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 65; (o) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 64, and the antisense strand comprising a second nucleic acid sequence selected from any one of SEQ ID NO: 70, SEQ ID NO: 72-74; (p) the sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 88; (q) the sense strand comprising a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 91; (r) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 101, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 102; (s) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 103, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 104; (t) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 105, and the antisense strand comprising a second nucleic acid sequence selected from any one of SEQ ID NO: 65, SEQ ID NO: 106-108; (u) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 109, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 65; (v) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 110, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 40; (w) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 111, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO: 112; (x) the sense strand comprises a first nucleic acid sequence of SEQ ID NO: 113, and the antisense strand comprises a second nucleic acid sequence of SEQ ID NO: 114; and (y) the sense strand comprising a first nucleic acid sequence of SEQ ID NO: 115, and the antisense strand comprising a second nucleic acid sequence of SEQ ID NO:

116. A MAPT RNAi agent comprising a pair of nucleic acid sequences selected from the group consisting of:

27. The sense strand and the antisense strand are (a) the sense strand having a first nucleic acid sequence of SEQ ID NO: 63, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (b) the sense strand having a first nucleic acid sequence of SEQ ID NO:25, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:26; (c) the sense strand having a first nucleic acid sequence of SEQ ID NO:27, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:28; (d) the sense strand having a first nucleic acid sequence of SEQ ID NO:29, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:30; (e) the sense strand having a first nucleic acid sequence of SEQ ID NO:31, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:32; (f) the sense strand having a first nucleic acid sequence of SEQ ID NO: 33, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 34; (g) the sense strand having a first nucleic acid sequence of SEQ ID NO: 35, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 36; (h) the sense strand having a first nucleic acid sequence of SEQ ID NO: 37, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 38; (i) the sense strand having a first nucleic acid sequence of SEQ ID NO: 39, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (j) the sense strand having a first nucleic acid sequence of SEQ ID NO: 41, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 42; (k) the sense strand having a first nucleic acid sequence of SEQ ID NO: 43, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 44; (l) the sense strand having a first nucleic acid sequence of SEQ ID NO: 45, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 46; (m) the sense strand having a first nucleic acid sequence of SEQ ID NO: 47, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 48; (n) the sense strand having a first nucleic acid sequence selected from any one of SEQ ID NO: 64, SEQ ID NO: 66-69, SEQ ID NO: 71, SEQ ID NO: 75-86, SEQ ID NO: 93-100, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (o) the sense strand having a first nucleic acid sequence of SEQ ID NO: 64, and the antisense strand having a second nucleic acid sequence selected from any one of SEQ ID NO: 70, SEQ ID NO: 72-74; (p) the sense strand having a first nucleic acid sequence selected from SEQ ID NO: 87 or SEQ ID NO: 89, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 88; (q) the sense strand having a first nucleic acid sequence selected from SEQ ID NO: 90 or SEQ ID NO: 92, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 91; (r) the sense strand having a first nucleic acid sequence of SEQ ID NO: 101, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 102; (s) the sense strand having a first nucleic acid sequence of SEQ ID NO: 103, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 104; (t) the sense strand having a first nucleic acid sequence of SEQ ID NO: 105, and the antisense strand having a second nucleic acid sequence selected from any one of SEQ ID NO: 65, SEQ ID NO: 106-108; (u) the sense strand having a first nucleic acid sequence of SEQ ID NO: 109, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 65; (v) the sense strand having a first nucleic acid sequence of SEQ ID NO: 110, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 40; (w) the sense strand having a first nucleic acid sequence of SEQ ID NO:111, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:112; (x) the sense strand having a first nucleic acid sequence of SEQ ID NO: 113, and the antisense strand having a second nucleic acid sequence of SEQ ID NO: 114; and (y) the sense strand having a first nucleic acid sequence of SEQ ID NO: 115, and the antisense strand having a second nucleic acid sequence of SEQ ID NO:

116.

27. The MAPT RNAi agent of claim 26, having a pair of nucleic acid sequences selected from the group consisting of:

28. 28. The MAPT RNAi agent of any one of claims 1-27, wherein the sense strand has a delivery moiety conjugated to the 5' or 3' end of the sense strand.

29. 29. The MAPT RNAi agent of any one of claims 1-28, wherein the sense strand has a delivery moiety conjugated to a nucleotide of the sense strand.

30. 30. The MAPT RNAi agent of claim 28, wherein the delivery moiety is conjugated to the 3' end of the sense strand, optionally via a linker.

31. A pharmaceutical composition comprising the MAPT RNAi agent of any one of claims 1 to 30 and a pharma- ceutically acceptable carrier.

32. 32. A method of reducing MAPT expression in a patient in need thereof, comprising administering to said patient an effective amount of the MAPT RNAi agent of any one of claims 1 to 30, or the pharmaceutical composition of claim 31.

33. 32. A method of treating a tauopathy in a patient in need thereof, comprising administering to the patient an effective amount of the MAPT RNAi agent of any one of claims 1 to 30, or the pharmaceutical composition of claim 31.

34. The tauopathy may be Alzheimer's disease (AD), frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), behavioral variant frontotemporal dementia (bvFTD), non-fluent variant primary progressive aphasia (nfvPPA), Parkinson's disease, Pick's disease (PiD), primary semantic progressive aphasia (PPA-S), primary logopenic progressive aphasia PPA- L), multisystem tauopathy with dementia in early life (MSTD), neurofibrillary tangle dementia (NFT), FTD with motor neuron disease, progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis / parkinsonism-dementia complex (ALS-PDC), argyrophilic grain dementia (AGD), British amyloid angiopathy, cerebral amyloid angiopathy, chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), Creutzfeldt-Jakob disease, Chronic Jakob disease (CJD), dementia pugilistica, diffuse neurofibrillary tangles with calcification (idiopathic basal ganglia calcification), Down's syndrome, epilepsy, Gerstmann-Straussler-Scheinker syndrome, Hallervorden-Spatz disease, Huntington's disease, inclusion body myositis, lead toxic encephalopathy, Rittich-Bodig disease, meningioangiomatosis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C (NP-C), non-Guamanian encephalopathy with neurofibrillary tangles 34. The method of claim 33, wherein the disease is selected from motor neuron disease, encephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, neurofibrillary tangle senile dementia, neurofibrillary senile dementia, argyrophilic grain disease, ganglioglioma, gangliocytoma, subacute sclerosing panencephalitis, tuberous sclerosis, lipofuscinosis, primary age-related tauopathy (geriatric tauopathy, PART), or globular glial tauopathy (GGT).

35. 35. The method of claim 33 or 34, wherein the tauopathy is Alzheimer's disease (AD), frontotemporal dementia (FTD), or progressive supranuclear palsy (PSP).

36. 36. The method of any one of claims 33-35, wherein the MAPT RNAi agent is administered to the patient via intrathecal, intracerebroventricular, or intracisternal injection.

37. 1. A method for reducing MAPT expression in a cell, comprising: Introducing into said cell a MAPT RNAi agent according to any one of claims 1 to 30; incubating said cells for a time sufficient to degrade MAPT mRNA, thereby reducing MAPT expression in said cells.

38. A MAPT RNAi agent according to any one of claims 1 to 30, or a pharmaceutical composition according to claim 31, for use in therapy.

39. A MAPT RNAi agent according to any one of claims 1 to 30, or a pharmaceutical composition according to claim 31, for use in reducing MAPT expression.

40. The MAPT RNAi agent according to any one of claims 1 to 30, or the pharmaceutical composition according to claim 31, for use in the treatment of a tauopathy.

41. The tauopathy may be Alzheimer's disease (AD), frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), behavioral variant frontotemporal dementia (bvFTD), non-fluent variant primary progressive aphasia (nfvPPA), Parkinson's disease, Pick's disease (PiD), primary semantic progressive aphasia (PPA-S), primary logopenic progressive aphasia (PPA-L), or the like. ), multisystem tauopathy with dementia in early life (MSTD), neurofibrillary tangle dementia (NFT), FTD with motor neuron disease, progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis / parkinsonism-dementia complex (ALS-PDC), argyrophilic grain dementia (AGD), British amyloid angiopathy, cerebral amyloid angiopathy, chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), Creutzfeldt-Jakob disease, Cobb's disease (CJD), dementia pugilistica, diffuse neurofibrillary tangles with calcification (idiopathic basal ganglia calcification), Down's syndrome, epilepsy, Gerstmann-Straussler-Scheinker syndrome, Hallervorden-Spatz disease, Huntington's disease, inclusion body myositis, lead toxic encephalopathy, Ritiko-Bodig disease, meningioangiomatosis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C (NP-C), non-guanine motor neurons with neurofibrillary tangles 41. The MAPT RNAi agent or pharmaceutical composition for use according to claim 40, wherein the MAPT RNAi agent or pharmaceutical composition is selected from the group consisting of encephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, neurofibrillary tangle senile dementia, neurofibrillary senile dementia, argyrophilic grain disease, ganglioglioma, gangliocytoma, subacute sclerosing panencephalitis, tuberous sclerosis, lipofuscinosis, primary age-related tauopathy (geriatric tauopathy, PART), or globular glial tauopathy (GGT).

42. 42. The MAPT RNAi agent or pharmaceutical composition for use according to claim 40 or 41, wherein the tauopathy is Alzheimer's disease (AD), frontotemporal dementia (FTD), or progressive supranuclear palsy (PSP).

43. 31. Use of the MAPT RNAi agent of any one of claims 1 to 30 in the manufacture of a medicament for the treatment of a tauopathy.

44. The tauopathy may be Alzheimer's disease (AD), frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), behavioral variant frontotemporal dementia (bvFTD), non-fluent variant primary progressive aphasia (nfvPPA), Parkinson's disease, Pick's disease (PiD), primary semantic progressive aphasia (PPA-S), primary logopenic progressive aphasia (PPA -L), multisystem tauopathy with dementia in early life (MSTD), neurofibrillary tangle (NFT) dementia, FTD with motor neuron disease, progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis / parkinsonism-dementia complex (ALS-PDC), argyrophilic grain dementia (AGD), British amyloid angiopathy, cerebral amyloid angiopathy, chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), Creutzfeldt-Jakob disease, CrJD, dementia pugilistica, diffuse neurofibrillary tangles with calcification (idiopathic basal ganglia calcification), Down's syndrome, epilepsy, Gerstmann-Sträussler-Scheinker syndrome, Hallervorden-Spatz disease, Huntington's disease, inclusion body myositis, lead toxic encephalopathy, Ritiko-Bodig disease, meningioangiomatosis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C (NP-C), non-Guamanian neurofibrillary tangles 44. The use according to claim 43, wherein the tauopathy is selected from motor neuron disease, encephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, neurofibrillary tangle senile dementia, neurofibrillary senile dementia, argyrophilic grain disease, ganglioglioma, gangliocytoma, subacute sclerosing panencephalitis, tuberous sclerosis, lipofuscinosis, primary age-related tauopathy (geriatric tauopathy, PART), or globular glial tauopathy (GGT).

45. 45. The use of claim 43 or 44, wherein the tauopathy is Alzheimer's disease (AD), frontotemporal dementia (FTD), or progressive supranuclear palsy (PSP).

Citation Information

Patent Citations

  • Oligonucleotides for MAPT modulation

    WO2021188626A1